Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Israel, G. Colice, J. Grigg, R. Martin, W. van Aalderen, P. Dorinsky, D. Postma, N. Roche, A. Burden, J. von Ziegenweidt, F. Barion, E. Hillyer, V. Thomas, D. Price (Boston, Washington, Denver, Morrisville, United States Of America; London, Cambridge, Aberdeen, United Kingdom; Amsterdam, Groningen, Netherlands; Paris, France). Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy. Eur Respir J 2013; 42: Suppl. 57, 3826

Member's Comments

No comment yet.

Related content which might interest you: Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Inhaler preference comparing two alternative dual bronchodilator regimens Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Country-specific cost-effectiveness of early intervention with budesonide in mild asthma Source: Eur Respir J 2004; 24 : 568-574 Year: 2004 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA Source: International Congress 2014 – Paediatric asthma: what is new for the clinician? Year: 2014 Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Real world effectiveness of changing combination therapy in primary care asthma management Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013